Smith, Kline & French

Last updated
Smith, Kline & French
Industry Pharmaceutical
Founded1830 (1830)
Founder John K. Smith
Defunct1989;35 years ago (1989)
FateMerged with The Beecham Group plc to form SmithKline Beecham
SuccessorSmithKline Beecham (1989–2000)
GlaxoSmithKline (2000–present)

Smith, Kline & French (SKF) was an American pharmaceutical company.

Contents

History

In 1830, John K. Smith opened a drugstore in Philadelphia, and his younger brother, George, joined him in 1841 to form John K Smith & Co. In 1865, Mahlon Kline joined the company, as a bookkeeper. In 1875, he took on additional responsibilities as a salesman and added many new and large accounts, as a reward the company, Mahlon K Smith and Company, was renamed into Smith, Kline and Company. [1]

In 1891, Smith, Kline and Company acquired French, Richards and Company, founded in 1844 by Clayton French and William Richards, which provided the company with a greater portfolio of consumer brands. The combined business became the Smith, Kline and French Company. [1]

In 1932, SKF chemist Gordon Alles was awarded a patent for amphetamine. [1]

In 1968, the company acquired Recherche et Industrie Thérapeutiques in Belgium. [2]

SmithKline acquired Allergan in 1982, an eye and skincare business, and merged with Beckman Instruments, Inc., a company specialising in diagnostics and measurement instruments and supplies. After the merger the company was renamed SmithKline Beckman. [1]

SmithKline Beckman and Beecham Group merged in 1989 to form SmithKline Beecham plc. In 2000, SmithKline Beecham merged with Glaxo Wellcome to form GlaxoSmithKline (GSK). [3]

Related Research Articles

<span class="mw-page-title-main">Ribena</span> Blackcurrant-based drink

Ribena is a brand of blackcurrant-based soft drink, and fruit drink concentrate designed to be mixed with water. It is available in bottles, cans and multi-packs. Originally of English origin, it was produced by the pharmaceutical company GlaxoSmithKline (GSK) until 2013, when the brand was sold to Japanese beverage conglomerate Suntory.

<span class="mw-page-title-main">GSK plc</span> UK healthcare company

GSK plc is a British multinational pharmaceutical and biotechnology company with global headquarters in London. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.

<span class="mw-page-title-main">Horlicks</span> Sweet malted milk hot drink powder

Horlicks is a sweet malted milk hot drink powder developed by founders James and William Horlick. It was first sold as "Horlick's Infant and Invalids Food", soon adding "aged and travellers" to their label. In the early 20th century, it was sold as a powdered meal replacement drink mix.

<span class="mw-page-title-main">FTSE 100 Index</span> Share index of the London Stock Exchange

The Financial Times Stock Exchange 100 Index, also called the FTSE 100 Index, FTSE 100, FTSE, or, informally, the "Footsie", is a share index of the 100 companies listed on the London Stock Exchange with the highest market capitalisation. The index is maintained by the FTSE Group, a subsidiary of the London Stock Exchange Group.

Lucozade is a British brand of soft drinks and energy drinks manufactured and marketed by the Japanese company Suntory. Created as "Glucozade" in the UK in 1927 by a Newcastle pharmacist, William Walker Hunter, it was acquired by the British pharmaceutical company Beecham's in 1938 and sold as Lucozade, an energy drink for the sick. Its advertising slogan was "Lucozade aids recovery". It was sold mostly in pharmacies up until the 1980s before it was more readily available as a sports drink in shops across the UK.

<span class="mw-page-title-main">Beckman Coulter</span> American corporation

Beckman Coulter, Inc. is a Danaher Corporation company that develops, manufactures, and markets products that simplify, automate, and innovate upon complex biomedical testing. It operates in two industries: Diagnostics and Life Sciences. For more than 80 years, Beckman Coulter Inc. has helped healthcare and laboratory professionals, pharmaceutical and biotechnology companies, universities, medical schools, and research institutions worldwide.

<span class="mw-page-title-main">Human Genome Sciences</span> Former American pharmaceutical company, acquired by GlaxoSmithKline.

Human Genome Sciences (HGS) was a biopharmaceutical corporation founded in 1992 by Craig Venter, Alan Walton and Wally Steinberg. It uses the human DNA sequence to develop protein and antibody drugs. It had drugs under development to treat such diseases as hepatitis C, systemic lupus erythmatosis, anthrax, and cancer. It collaborated with other biotechnology and pharmaceutical companies for development partnerships and licensing.

<span class="mw-page-title-main">Dyclonine</span> Anesthetic

Dyclonine (Dyclocaine) is an oral anaesthetic that is the active ingredient of Sucrets, an over-the-counter throat lozenge. It is also found in some varieties of the Cepacol sore throat spray. It is a local anesthetic, used topically as the hydrochloride salt.

Recherche et Industrie Thérapeutiques (R.I.T.) was founded in Genval, Belgium, as a penicillin factory in 1945 by Dr Pieter De Somer, who later became the founder of the Rega Institute for Medical Research and rector of the Katholieke Universiteit Leuven. The industrialist Jean Lannoye provided the funding for the company. The company started its vaccine research and production in the 1950s. The present CEO of the company is Roger Connor.

<span class="mw-page-title-main">Beecham Group</span> Former British pharmaceutical company (1859–1989)

The Beecham Group plc was a British pharmaceutical company. It was once a constituent of the FTSE 100 Index. Founded by Thomas Beecham who opened the first factory in St Helens, Lancashire in 1859, Beecham focused on marketing the business by advertising in newspapers and using a network of wholesale agents in northern England and in London, rapidly building up the business. In August 1859 he created the slogan for Beecham's Pills: "Worth a guinea a box", considered to be the world's first advertising slogan, which helped the business become a global brand.

<span class="mw-page-title-main">Andrew Witty</span> British business executive (born 1964)

Sir Andrew Philip Witty is a British business executive, who is the current chief executive officer (CEO) of UnitedHealth Group. He was also the CEO of GlaxoSmithKline between 2008 and 2017. He formerly held the role of chancellor of the University of Nottingham.

GlaxoSmithKline Pakistan is a Pakistani pharmaceutical company which is a subsidiary of British company GSK. It is the largest pharmaceutical company in Pakistan.

The pharmaceutical industry in the United Kingdom directly employs around 73,000 people and in 2007 contributed £8.4 billion to the UK's GDP and invested a total of £3.9 billion in research and development. In 2007 exports of pharmaceutical products from the UK totalled £14.6 billion, creating a trade surplus in pharmaceutical products of £4.3 billion.

Christopher v. SmithKline Beecham Corp., 567 U.S. 142 (2012), is a US labor law case of the United States Supreme Court. It held that pharmaceutical sales representatives were not eligible for overtime pay. The court ruled in a majority opinion written by Justice Samuel Alito that sales representatives were classified as "outside salesmen" who are exempt from the Department of Labor's regulations regarding overtime pay.

<span class="mw-page-title-main">Study 329</span> Scientific article

Study 329 was a clinical trial which was conducted in North America from 1994 to 1998 to study the efficacy of paroxetine, an SSRI anti-depressant, in treating 12- to 18-year-olds diagnosed with major depressive disorder. Led by Martin Keller, then professor of psychiatry at Brown University, and funded by the British pharmaceutical company SmithKline Beecham—known since 2000 as GlaxoSmithKline (GSK)—the study compared paroxetine with imipramine, a tricyclic antidepressant, and placebo. SmithKline Beecham had released paroxetine in 1991, marketing it as Paxil in North America and Seroxat in the UK. The drug attracted sales of $11.7 billion in the United States alone from 1997 to 2006, including $2.12 billion in 2002, the year before it lost its patent.

Jean-Pierre Garnier is a French businessman, and a former chief executive of GlaxoSmithKline.

<span class="mw-page-title-main">Emma Walmsley</span> British businesswoman

Dame Emma Natasha Walmsley is the chief executive officer (CEO) of GlaxoSmithKline. She succeeded Sir Andrew Witty, who retired in March 2017. Before GSK, she worked for L'Oréal for 17 years, and was a non-executive director of Diageo until September 2016. She grew up in Barrow-in-Furness, Cumbria, England.

<span class="mw-page-title-main">New Frontiers Science Park</span> Science park, former research centre in Harlow, Essex

The New Frontiers Science Park is a science park in Essex, on a redeveloped research site of GlaxoSmithKline (GSK).

References

  1. 1 2 3 4 Glenn E. Ullyot; Barbara Hodsdon Ullyot; Leo B. Slater (2000). "The Metamorphosis of Smith-Kline & French Laboratories to Smith Kline Beecham: 1925-1998" (PDF). Bull. Hist. Chem. University of Illinois at Urbana-Champaign, School of Chemical Sciences. 25 (1). Retrieved December 16, 2017.
  2. "Gates Foundation Finances Leuven University Research for Coronavirus Treatment". The Low Countries. 26 March 2020. Retrieved 20 February 2023.
  3. Petersen, Andrew Ross Sorkin With Melody (17 January 2000). "Glaxo and SmithKline Agree To Form Largest Drugmaker". The New York Times. ISSN   0362-4331 . Retrieved 25 June 2020.